Investor Presentaiton
Financial Highlights
Income Statement
EGP'000
Revenue
30 June 2018
(Unaudited)
865,853
(446,660)
419,193
30 June 2017
(Unaudited)
685,133
(366,867)
318,266
Cost of sales
Gross profit
Marketing and advertising expenses
(41,442)
(29,568)
Administrative expenses
(78,372)
(60,154)
Other expenses
(5,995)
Operating profit
293,384
224,243
Finance income
(4,301)
18,121
(16,316)
1,805
28,819
Finance cost
(18,168)
Net finance income/(cost)
10,651
Profit before tax
304,035
226,048
Income tax expense
(89,675)
(66,048)
Profit for the period
214,360
160,000
Profit attributed to:
Owners of the Company
Non-controlling interest
Earnings per share (expressed in EGP):
Basic and diluted earnings per share
216,462
155,344
(2,102)
4,656
214,360
160,000
1.44
1.04
Revenues increased 26% to EGP
866 million in 1H2018, driven
primarily by improved pricing as
the Group capitalised on the
inflationary environment it
operates within and successfully
targeted a larger number of
higher-margin walk-in patients.
The Group's strong revenue
performance came despite the
slow period during the holy
month of Ramadan.
Gross profit increased at a rate
faster than revenues, closing at
EGP 419 million in 1H2018 or
32% higher y-o-y. Gross profit
improved thanks to a higher
contribution from higher-margin
walk-in patients, a favourable test
mix and management's success in
controlling costs amidst an
inflationary environment. Gross
profit margin rose two
percentage points to 48% versus
46% recorded in 1H2017.
EBITDA grew 29% to EGP 329 million in 1H2018 compared to EGP 255 million in the same period last year. The Group's EBITDA margin improved to 38%
compared to 37% in 1H2017. Excluding the Nigerian operation, EBITDA growth would have been 32% in 1H2018 with an EBITDA margin of 40%.
32
INTEGRATED DIAGNOSTICS HOLDINGSView entire presentation